Silo Pharma, Inc. — Director's Dealing 2025

May 28, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silo Pharma, Inc. (SILO)
CIK: 0001514183
Period of Report: 2025-05-23

Reporting Person: Ryweck Daniel E. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-23	Options (right to buy)	$0.4290	A	50000	Acquired	2035-05-23	Common Stock (50000)	Direct

Footnotes

F1: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant.